SG Cowen analyst comment on Genentech data

SG Cowen analyst Eric Schmidt said that Phase II data from three studies of DNA's recombinant humanized monoclonal antibody against VEGF, which will be presented at the American Society of Clinical Oncology meeting in New Orleans next month, may not live up to high Street expectations. He said that six episodes of sudden and life threatening hemoptysis (expectoration of blood) observed in a 99-patient Phase II study to treat non-small cell lung cancer may surprise some investors. ...